Akcea Therapeutics (NASDAQ: AKCA) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a treatment for the nerves damage caused by the rare disease hereditary transthyretin amyloidosis.
Sponsored · Webinar
A discussion on business drivers, technical considerations, special requirements of cell and gene product manufacturing & digitization strategy
Global OT/IT Quality Services
Sponsored · Video
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace
Sponsored · Whitepaper
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson
